Evidence map›Paper›PMID 36145706›Full record

ArticlePharmaceutics2022

Complexation: An Interesting Pathway for Combining Two APIs at the Solid State.

Fucheng Leng, Oleksii Shemchuk, Koen Robeyns, Tom Leyssens

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Fucheng LengInstitute of Condensed Matter and Nanosciences, Université Catholique de Louvain, 1 Place Louis Pasteur, B-1348 Louvain-La-Neuve, Belgium.
Oleksii ShemchukInstitute of Condensed Matter and Nanosciences, Université Catholique de Louvain, 1 Place Louis Pasteur, B-1348 Louvain-La-Neuve, Belgium.ORCID 0000-0003-3003-3922
Koen RobeynsInstitute of Condensed Matter and Nanosciences, Université Catholique de Louvain, 1 Place Louis Pasteur, B-1348 Louvain-La-Neuve, Belgium.ORCID 0000-0002-4763-4217
Tom LeyssensInstitute of Condensed Matter and Nanosciences, Université Catholique de Louvain, 1 Place Louis Pasteur, B-1348 Louvain-La-Neuve, Belgium.ORCID 0000-0001-7916-1373
UCLouvain · BE

Funding

Fund for Scientific Research PDR T.0.149.19Fund for Scientific Research PDR T.262.20
6 · The paper itself

Abstract

Combining different drugs into a single crystal form is one of the current challenges in crystal engineering, with the number of reported multi-drug solid forms remaining limited. This paper builds upon an efficient approach to combining Active Pharmaceutical Ingredients (APIs) containing carboxylic groups in their structure with APIs containing pyridine moieties. By transforming the former into their zinc salts, they can be successfully combined with the pyridine-containing APIs. This work highlights the successfulness of this approach, as well as the improvement in the physical properties of the obtained solid forms.

Indexed as

crystal engineeringdrug–drug complexessolid statesolubility improvement

Identifiers

PMID36145706
PMCPMC9503796
OpenAlexW4296350756

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.